Overview

* Aurinia Q2 2025 total revenue rises 22% yr/yr to $70 mln

* Net income for Q2 2025 reaches $21.5 mln, up from $0.7 mln last year

* Co increases share repurchase plan by $150 mln, reflecting financial confidence

Outlook

* Aurinia raises 2025 revenue guidance to $260 mln-$270 mln

* Company ups 2025 LUPKYNIS sales forecast to $250 mln-$260 mln

* Aurinia plans clinical trials for aritinercept in autoimmune diseases

* Company sees growth driven by new lupus nephritis treatment guidelines

Result Drivers

* LUPKYNIS SALES - Co attributes 21% increase in net product sales to new treatment guidelines recommending LUPKYNIS as first-line therapy

* COLLABORATION REVENUE - License, collaboration and royalty revenue up 55% due to manufacturing services from partner Otsuka

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $66.57

Product mln

Revenue

Q2 EPS $0.16

Q2 Net $21.51

Income mln

Q2 $49.92

Operatin mln

g

Expenses

Q2 $20.08

Operatin mln

g Income

Q2 $22.16

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc ( AUPH ) is $10.85, about 16.6% above its July 30 closing price of $9.05

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)